The Institute of Cancer Research, London, is seeking licensees for a portfolio of assets that target hard-to-treat oncology driving proteins LMO2 and RAS. Using an innovative antibody fragment ...

At the ICR, I study the mechanisms of selective autophagy. We are focussed on with new strategies for therapy aimed at chromosomal translocation gene products, like LMO2 and translocation protein ...